Dataset Information

Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum ?-lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia.

ABSTRACT:

Background

The prevalence of extended-spectrum ?-lactamases (ESBLs) have been reported in clinical isolates obtained from various hospitals in Ethiopia. However, there is no data on the prevalence and antibiotic susceptibility patterns of CTX-M type ESBL produced by Gram-negative bacilli. The aim of this study was to determine the frequency and distribution of the bla_CTX-M genes and the susceptibility patterns in ESBL producing clinical isolates of Gram-negative bacilli in Jimma University Specialized Hospital (JUSH), southwest Ethiopia.

Methods

A total of 224 non-duplicate and pure isolates obtained from clinically apparent infections, were included in the study. Identification of the isolates was performed by MALDI-TOF mass spectrometry. Susceptibility testing and ESBL detection was performed using VITEK® 2, according to EUCAST v4.0 guidelines. Genotypic analysis was performed using Check-MDR CT103 Microarrays.

Results

Of the total 112 (50.0%) isolates screen positive for ESBLs, 63.4% (71/112) tested positive for ESBL encoding genes by Check-MDR array, which corresponds to 91.8% (67/73) of the total Enterobacteriaceae and 10.3% (4/39) of nonfermenting Gram-negative bacilli. Among the total ESBL gene positive isolates, 95.8% (68/71) carried bla_CTX-M genes with CTX-M group 1 type15 being predominant (66/68; 97.1% of CTX-M genes). The bla_CTX-M carrying Enterobacteriaceae (n =?64) isolates showed no resistance against imipenem and meropenem and a moderate resistance rate against tigecycline (14.1%), fosfomycin (10.9%) and amikacin (1.6%) suggesting the effectiveness of these antibiotics against most isolates. On the other hand, all the bla_CTX-M positive Enterobacteriaceae showed a multidrug resistant (MDR) phenotype with remarkable co-resistances (non-susceptibility rates) to aminoglycosides (92.2%), fluoroquinolones (78.1%) and trimethoprim/sulfamethoxazol (92.2%).

Conclusions

This study demonstrates a remarkably high prevalence of bla_CTX-M genes among ESBL-producing isolates. The high level of resistance to ?-lactam and non-?-lactam antibiotics as well as the trend to a MDR profile associated with the bla_CTX-M genes are alarming and emphasize the need for routine diagnostic antimicrobial susceptibility testing for appropriate choice of antimicrobial therapy.

PROVIDER: S-EPMC6196031 | BioStudies |

REPOSITORIES: biostudies

ACCESS DATA

Similar Datasets

Project description:<h4>Background</h4>Epidemiological data of cephalosporin-resistant Enterobacterales in Sub-Saharan Africa is still restricted, and in particular in Mozambique. The aim of this study was to detect and characterize extended-spectrum ?-lactamase (ESBL) - and plasmid-mediated AmpC (pAmpC)-producing clinical strains of Escherichia coli at Maputo Central Hospital (MCH), a 1000-bed reference hospital in Maputo, Mozambique.<h4>Methods</h4>A total of 230 clinical isolates of E. coli from urine (n?=?199) and blood cultures (n?=?31) were collected at MCH during August-November 2015. Antimicrobial susceptibility testing was performed by the disc diffusion method and interpreted according to EUCAST guidelines. Isolates with reduced susceptibility to 3rd generation cephalosporins were examined further; phenotypically for an ESBL-/AmpC-phenotype by combined disc methods and genetically for ESBL- and pAmpC-encoding genes by PCR and partial amplicon sequencing as well as genetic relatedness by ERIC-PCR.<h4>Results</h4>A total of 75 isolates with reduced susceptibility to cefotaxime and/or ceftazidime (n?=?75) from urine (n?=?58/199; 29%) and blood (n?=?17/31; 55%) were detected. All 75 isolates were phenotypically ESBL-positive and 25/75 (33%) of those also expressed an AmpC-phenotype. ESBL-PCR and amplicon sequencing revealed a majority of bla<sub>CTX-M</sub> (n?=?58/75; 77%) dominated by bla<sub>CTX-M-15</sub>. All AmpC-phenotype positive isolates (n?=?25/75; 33%) scored positive for one or more pAmpC-genes dominated by bla<sub>MOX/FOX</sub>. Multidrug resistance (resistance ? three antibiotic classes) was observed in all the 75 ESBL-positive isolates dominated by resistance to trimethoprim-sulfamethoxazole, ciprofloxacin and gentamicin. ERIC-PCR revealed genetic diversity among strains with minor clusters indicating intra-hospital spread.<h4>Conclusion</h4>We have observed a high prevalence of MDR pAmpC- and/or ESBL-producing clinical E. coli isolates with FOX/MOX and CTX-Ms as the major ?-lactamase types, respectively. ERIC-PCR analyses revealed genetic diversity and some clusters indicating within-hospital spread. The overall findings strongly support the urgent need for accurate and rapid diagnostic services to guide antibiotic treatment and improved infection control measures.

Project description:<h4>Background</h4>The increasing prevalence of broad-spectrum ampicillin-resistant and third-generation cephalosporin-resistant <i>Enterobacteriaceae</i>, particularly <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>, has become a global concern, with its clinical impacts on both human and veterinary medicine. This study examined the prevalence, antimicrobial susceptibility, and molecular genetic features of extended-spectrum β-lactamase (ESBL)-producing <i>E. coli</i> and <i>K. pneumoniae</i> isolates from 10 types of raw vegetables.<h4>Methods</h4>In total, 305 samples were collected from 9 markets in Nakhon Si Thammarat, Thailand, in 2020.<h4>Results</h4>ESBL-producing <i>E. coli</i> and <i>K. pneumoniae</i> isolates were found in 14 of the 305 samples obtained from 7 out of 10 types of vegetables (4.6% of the total). Further, 14 ESBL-producing <i>E. coli</i> (<i>n</i> = 5/14) and <i>K. pneumoniae</i> isolates (<i>n</i> = 9/14) (1.6% and 3.0%, respectively) were highly sensitive to β-lactam/carbapenem antibiotics (imipenem, 100%). ESBL-producing <i>E. coli</i> (<i>n</i> = 4) and <i>K. pneumoniae</i> isolates (<i>n</i> = 8) were also sensitive to non-β-lactam aminoglycosides (amikacin, 80.00% and 88.89%, respectively). ESBL producers were most resistant to β-lactam antibiotics, including ampicillin (85.71%) and the cephalosporins cefotaxime and ceftazidime (64.29%). The most frequently detected gene in ESBL-producing <i>E. coli</i> and <i>K. pneumoniae</i> was <i>bla<sub>SHV</sub></i> . However, two ESBL-producing <i>E. coli</i> isolates also carried three other ESBL-encoding variants, <i>bla<sub>TEM</sub></i> , <i>bla<sub>CTX-M1</sub></i> , <i>bla<sub>GES</sub> and bla<sub>TEM</sub>, bla<sub>SHV</sub>, bla<sub>CTX-M9</sub></i> , which may be due to their association with food chains and humans.<h4>Discussion</h4>Indeed, our results suggest that raw vegetables are an important source of ESBL-resistant <i>E. coli</i> and <i>K. pneumoniae</i>, which are potentially transmittable to humans via raw vegetable intake.

Project description:<h4>Background</h4>Shigella spp., facultative anaerobic bacilli of the family Enterobacteriaceae, are one of the most common causes of diarrheal diseases in human worldwide which have become a significant public health burden. So, we aimed to analyze the antimicrobial phenotypes and to elucidate the molecular mechanisms underlying resistance to cephalosporins and fluoroquinolones in Shigella isolates from patients with diarrhea in Shanxi Province.<h4>Results</h4>During 2006-2016, we isolated a total of 474 Shigella strains (including 337?S. flexneri and 137?S. sonnei). The isolates showed high rates of resistance to traditional antimicrobials, and 26, 18.1 and 3.0% of them exhibited resistance to cephalosporins, fluoroquinolones and co-resistance to cephalosporins and fluoroquinolones, respectively. Notably, 91.1% of these isolates, including 22 isolates that showed an ACTSuT profile, exhibited multidrug resistance (MDR). The resistance rates to cephalosporins in S. sonnei isolates were higher than those in S. flexneri. Conversely, the resistance rates to fluoroquinolones were considerably higher in S. flexneri isolates. Among the 123 cephalosporins-resistant isolates, the most common extended-spectrum beta-lactamase gene was bla<sub>TEM-1</sub>, followed by bla<sub>CTX-M</sub>, bla<sub>OXA-1</sub>, and bla<sub>SHV-12</sub>. Six subtypes of bla<sub>CTX-M</sub> were identified, bla<sub>CTX-M-14</sub> (n?=?36) and bla<sub>CTX-M-55</sub> (n?=?26) were found to be dominant. Of all the 86 isolates with resistance to fluoroquinolones and having at least one mutation (Ser83Leu, His211Tyr, or Asp87Gly) in the the quinolone resistance-determining regions of gyrA, 79 also had mutation of parC (Ser80Ile), whereas 7 contained plasmid-mediated quinolone resistance genes including qnrA, qnrB, qnrS, and aac(60)-Ib-cr. Furthermore, pulsed-field gel electrophoresis analysis (PFGE) showed a considerable genetic diversity in S. flexneri isolates. However, the S. sonnei isolates had a high genetic similarity.<h4>Conclusions</h4>Coexistence of diverse resistance genes causing the emergence and transmission of MDR might render the treatment of shigellosis difficult. Therefore, continuous surveillance might be needed to understand the actual disease burden and provide guidance for shigellosis.

Project description:<h4>Background</h4>Gram-negative ESKAPE bacteria are increasingly implicated in several difficult-to-treat infections in developed and developing countries. They are listed by the World Health Organization as resistant bacteria of critical priority in research.<h4>Objectives</h4>To determine the risk factors, prevalence, phenotypic profiles, genetic diversity and clonal relatedness of extended-spectrum ?-lactamase (ESBL)-producing multi-drug resistant (MDR) Gram-negative ESKAPE bacteria in the faecal carriage and clinical samples from patients in an urban, tertiary and a rural, district hospital in uMgungundlovu District, KwaZulu-Natal, South Africa.<h4>Methods</h4>This study took place in a district and tertiary hospital during a two-months period from May to June 2017 in uMgungundlovu district, South Africa. Rectal swabs collected from hospitalized patients, at admission, after 48 h and at discharge (whenever possible) formed the carriage sample while clinical isolates routinely processed in the microbiological laboratory during the sampling period were also collected and formed the clinical sample. Gram-negative ESKAPE bacteria were screened for ESBL production on selective MacConkey agar and confirmed using ROSCO kits. Minimum inhibitory concentrations were determined, and real-time and multiplex polymerase chain reaction were used to ascertain the presence of <i>bla</i> <sub>CTX-M</sub> group-1-2-9, <i>bla</i> <sub>CTX-M</sub> group 8/25, <i>bla</i> <sub>SHV</sub>, <i>bla</i> <sub>TEM</sub>, <i>bla</i> <sub>OXA-1-like</sub>, <i>bla</i> <sub>KPC</sub>, <i>bla</i> <sub>VIM</sub>, <i>bla</i> <sub>IMP</sub>, <i>bla</i> <sub>GES</sub> and AmpC genes. Genomic fingerprinting was also performed using ERIC-PCR. Risk factors for ESBL-mediating MDR Gram-negative ESKAPE colonization were ascertained by univariate and multivariate logistic regression analyses.<h4>Results</h4>Overall prevalence of carriage of ESBL-mediating MDR Gram-negative ESKAPE was 37.21% (16/43), 42.31% (11/26) and 57.14% (4/7) at admission, after 48 h and at discharge respectively. The prevalence of ESBL-mediating MDR Gram-negative ESKAPE bacteria in faecal carriage (46%) was higher than clinical samples (28%). Colonization was mainly associated with the referral from district to tertiary hospital with high statistical significance (OR: 14.40, 95% CI 0.98-210.84). <i>bla</i> <sub>CTX-M-group-9</sub>, <i>bla</i> <sub>CTX-M-group-1</sub> and <i>bla</i> <sub>SHV</sub> were the main resistance genes identified. Several patients carried more than two different isolates. A <i>Klebsiella pneumoniae</i> (K1) clone was circulating within wards and between hospitals.<h4>Conclusion</h4>The study highlights the high prevalence of ESBL-mediating MDR Gram-negative ESKAPE bacteria in carriage and clinical samples among hospitalized patients in uMgungundlovu, South Africa. The wide dissemination of these resistant ESKAPE bacteria in hospitals necessitates improvements in routine screening and reinforcement of infection, prevention and control measures.

Project description:<h4>Background</h4>Blood stream infections (BSI) caused by Extended Spectrum Beta-Lactamases (ESBLs) producing Enterobacteriaceae is a clinical challenge leading to high mortality, especially in developing countries. In this study, we sought to describe the epidemiology of ESBL-producing Escherichia coli strains isolated from Vietnamese individuals with BSI, to investigate the concordance of genotypic-phenotypic resistance, and clinical outcome of ESBL E. coli BSI.<h4>Methods</h4>A total of 459 hospitalized patients with BSI were screened between October 2014 and May 2016. 115 E. coli strains from 115 BSI patients were isolated and tested for antibiotic resistance using the VITEK®2 system. The ESBL phenotype was determined by double disk diffusion method following the guideline of Clinical and Laboratory Standards Institute. Screening for beta-lactamase (ESBL and carbapenemase) genes was performed using a multiplex-PCR assay.<h4>Results</h4>58% (67/115) of the E. coli strains were ESBL-producers and all were susceptible to both imipenem and meropenem. Resistance to third-generation cephalosporin was common, 70% (81/115) were cefotaxime-resistant and 45% (52/115) were ceftazidime-resistant. bla<sub>CTX-M</sub> was the most common ESBL gene detected (70%; 80/115) The sensitivity and specificity of bla<sub>CTX-M</sub>-detection to predict the ESBL phenotype was 87% (76-93% 95% CI) and 54% (39-48% 95% CI), respectively. 28%% (22/80) of bla<sub>CTX-M</sub> were classified as non-ESBL producers by phenotypic testing for ESBL production. The detection of bla<sub>CTX-M</sub> in ESBL-negative E. coli BSI was associated with fatal clinical outcome (27%; 6/22 versus 8%; 2/26, p = 0.07).<h4>Conclusion</h4>A high prevalence of ESBL-producing E. coli isolates harbouring bla<sub>CTX-M</sub> was observed in BSI patients in Vietnam. The genotypic detection of bla<sub>CTX-M</sub> may have added benefit in optimizing and guiding empirical antibiotic therapy of E. coli BSI to improve clinical outcome.